IMAX Crushes Q3 Revenue Record, But Valuation and Backlog Risks Persist

What happened

IMAX reported record Q3 revenue of $175 million and record global box office of $712 million, far surpassing the Q2 figures of $102.8 million and $284.8 million, respectively. This blowout quarter confirms strong demand for premium large-format cinema, driven by a dense slate of blockbusters. However, the company's backlog declined to 421 systems as of Q2 2026, down from 501 a year earlier, with 17 Greater China locations canceled, and the next update may show further attrition. IMAX's Greater China subsidiary earnings fell sharply to $8.1 million in the first half of 2026 from $23.7 million a year earlier, indicating ongoing structural weakness in its largest market. At a current price near $43.40, with a P/E of 57.8 and EV/EBITDA of 18.8, the stock already reflects these strong results, leaving little margin of safety if the box office momentum slows or China deteriorates further.

Implication

The record Q3 numbers support the thesis that IMAX can capture outsized box office share on tentpole films, but this was already priced in at current multiples. The backlog decline and China cancellations are not addressed by strong box office alone; they impact future network growth and recurring revenue. If the next quarterly filing shows backlog below 421 or additional China restructuring, the stock could face downward pressure despite record results. Conversely, if the company can stabilize backlog and show continued ex-China signings, the premium valuation may be justified. We maintain a WAIT rating with an attractive entry around $37 and would trim above $48, as the risk-reward is balanced but not compelling at current levels.

Thesis delta

The record Q3 results slightly strengthen the bull case, as IMAX continues to demonstrate exceptional premium-format demand and revenue scaling. However, the core concerns from the master report—declining backlog, China weakness, and already-stretched valuation—remain unchanged. Therefore, the thesis remains WAIT: the strong quarter reduces downside risk but does not justify buying at current levels; we still prefer accumulating only on a pullback toward $37 or on evidence that backlog and China stabilize.